Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $7.2952W HIGH $13.20
Volume
124.10 K
Value Traded
2.46 M
Short % Float
4.32%
+2.25%Week
+10.68%1 Month
+32%3 Month
+39.55%6 Month
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
265.59 M
EPS (TTM)
0.43
P/E Ratio
30.68
Ent. Value
285.05 M
Total Shares
20.19 M
Float Shares
18.80 M
Insiders
5.58%
Institutions
77.46%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
INFU Catalyst Timeline
Dated clinical, regulatory and corporate events for InfuSystem Holdings, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for InfuSystem Holdings, Inc.
6Total events
0Upcoming
0Tier-1 (high impact)
2025 to 2026Coverage
Event history 5
▲Product LaunchPost-Market
Launch of Pneumatic Compression Devices (PCDs) and Adjustable Compression Wraps (ACWs) with first manufacturer
Wound Caresource ↗
Past FDA Catalysts and PDUFA Decisions
How INFU actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
No drug pipeline
InfuSystem Holdings, Inc. is a medical device company. The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every INFU program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Steele Barry GOfficer (Executive VP and CFO) | Disposition | -3,800 117,767 held | $8.90 | 05/18/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in INFU
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| PARKMAN HEALTHCARE PARTNERS LLC | 1.1 % (-15.4 %) | 5.23 M | 251.57 K | -9.78% ( -27.27 K) |
INFU Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How INFU ranks across every disease it competes in
Competitive Position is a premium feature
See how INFU ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialINFU News
-INFU
Sep 17, 2026InfuSystem to Host Investor Webcast on September 24, 2026
InfuSystem has announced that it will host an investor webcast on September 24, 2026. This event aims to improve communication with investors and provide updates on the company's progress. The webcast reflects the company's commitment to transparency and investor engagement.
Read more →-INFU
Aug 4, 2026▲ +33.6%on this news
InfuSystem Announces Financial Results for Second Quarter 2026
InfuSystem has announced its financial results for the second quarter of 2026. The announcement was made from Rochester Hills, Michigan. Further details regarding the financial performance were not provided in the article.
Read more →-INFU
Jul 28, 2026▲ +6%on this news
InfuSystem to Report Second Quarter 2026 Financial Results on August 4, 2026
InfuSystem has announced that it will report its financial results for the second quarter of 2026 on August 4, 2026. This announcement is part of the company's regular financial reporting schedule. Investors and stakeholders will be able to assess the company's performance during this period once the results are disclosed.
Read more →-INFU
May 18, 2026InfuSystem Holdings, Inc. 3851 W. Hamlin Road Rochester Hills, MI 48309 (248) 291-1210 Contact Barry Steele Chief Financial Officer (248) 260-2211 InfuSystem Announces $20 Million Stock Repurchase Program Rochester Hills
InfuSystem Holdings, Inc. has announced a new stock repurchase program, allowing for the repurchase of up to $20 million of its outstanding common stock from July 1, 2026, to June 30, 2028. This program supersedes a previous authorization set to expire soon and is intended to enhance shareholder value. CEO Carrie Lachance emphasized the company's confidence in its growth strategy and the strength of its balance sheet, while also maintaining a focus on strategic investments for sustainable growth.
Read more →-INFU
May 7, 2026▼ -11.5%on this news
InfuSystem Holdings, Inc. 3851 W. Hamlin Road Rochester Hills, MI 48309 (248) 291-1210 Contact Barry Steele Chief Financial Officer (248) 260-2211 InfuSystem Announces Financial Results for First Quarter 2026 Net Revenue
InfuSystem Holdings, Inc. reported its financial results for the first quarter of 2026, revealing a net revenue of $33.7 million, marking a 3% decline from the previous year. While there were positive gains in Patient Services and an improvement in adjusted EBITDA margins, the Device Solutions segment experienced a significant 17% decrease in net revenue. The company reaffirmed its full-year guidance and highlighted continued growth potential in the wound care category, alongside the successful implementation of a new ERP system intended to boost operational efficiency.
Read more →-INFU
Apr 30, 2026InfuSystem Holdings, Inc. 3851 W. Hamlin Road Rochester Hills, MI 48309 248-291-1210 FOR IMMEDIATE RELEASE CONTACT Barry Steele Chief Financial Officer 248-260-2211 InfuSystem to Report First Quarter 2026 Financial Resul
InfuSystem Holdings, Inc. has announced that it will report its first quarter 2026 financial results on May 7, 2026, before market opens. Following the release, the company will host an investor conference call at 9:00 a.m. Eastern Time to discuss these results. InfuSystem is noted as a prominent provider of healthcare services related to durable medical equipment, supporting outpatient care effectively.
Read more →-INFU
Mar 16, 2026InfuSystem Holdings, Inc. 3851 W. Hamlin Road Rochester Hills, MI 48309 (248) 291-1210 Contact Barry Steele Chief Financial Officer (248) 260-2211 InfuSystem to Participate at 38th Annual ROTH Conference on
InfuSystem Holdings, Inc. will participate in the 38th Annual ROTH Conference on March 23, 2026, at The Ritz-Carlton Laguna Niguel, California. Company executives, including CEO Carrie Lachance and CFO Barry Steele, will host one-on-one meetings for investors. InfuSystem specializes in facilitating outpatient care within the durable medical equipment sector through its Patient Services and Device Solutions platforms, providing comprehensive support for healthcare providers.
Read more →-INFU
Feb 27, 2026q25investorpr Investor Presentation
InfuSystem's recent investor presentation highlights its ongoing growth and strategic initiatives aimed at enhancing patient care through medical equipment and services. The company has demonstrated a strong financial performance, achieving record revenues for seven consecutive years and an expected adjusted EBITDA of $31.5 million in 2025. InfuSystem's expansion into multiple therapy areas and robust partnerships with leading hospital systems across the U.S. positions it favorably within the healthcare market. The presentation also emphasizes a comprehensive approach to patient support and outcomes, contributing to its successful business model.
Read more →-INFU
Feb 24, 2026▲ +13.5%on this newsshared move
InfuSystem Announces Financial Results for Fourth Quarter and Full Year 2025
InfuSystem Holdings, Inc. reported strong financial results for 2025, marking its seventh consecutive year of record net revenues at $143.4 million, a 6% increase from the previous year. Net income surged by 183% to $6.6 million, and Adjusted EBITDA rose by 24% to $31.5 million. However, the company anticipates a revenue decrease of $7.1 million due to a restructuring of a major biomedical services contract, though it still expects overall revenue growth of 6% to 8% in 2026.
Read more →-INFU
Feb 24, 2026▲ +13.5%on this newsshared move
InfuSystem Holdings, Inc. 3851 W. Hamlin Road Rochester Hills, MI 48309 (248) 291-1210 Contact Barry Steele Chief Financial Officer (248) 260-2211 InfuSystem Announces Financial Results for Fourth Quarter and Full Year 2
InfuSystem Holdings, Inc. reported financial results for the fourth quarter and full year 2025, showcasing continued growth and profitability. The company achieved record net revenues of $143.4 million for 2025, with a 6% increase compared to the previous year, and a substantial net income rise of 183%. Despite a decrease in net cash from operations by 10%, management remains optimistic about ongoing initiatives to enhance growth, including a new revenue cycle management platform and establishing new relationships in the healthcare sector.
Read more →-INFU
Feb 17, 2026InfuSystem to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026
InfuSystem Holdings, Inc. will announce its preliminary financial results for the fourth quarter and full year 2025 on February 24, 2026. A conference call is scheduled for the same day at 9:00 a.m. ET to discuss these results. The company operates as a healthcare service provider, focusing on outpatient care and durable medical equipment.
Read more →-INFU
Feb 17, 2026InfuSystem Holdings, Inc. 3851 W. Hamlin Road Rochester Hills, MI 48309 248-291-1210 FOR IMMEDIATE RELEASE CONTACT Barry Steele Chief Financial Officer 248-260-2211 InfuSystem to Report Fourth Quarter and Full Year 2025
InfuSystem Holdings, Inc. announced that it will release its preliminary fourth quarter and full year 2025 financial results on February 24, 2026, prior to market opening. In conjunction with this release, the company will host a conference call at 9:00 a.m. Eastern Time to discuss the results. InfuSystem specializes in providing outpatient care service solutions for durable medical equipment manufacturers and healthcare providers.
Read more →-INFU
Dec 10, 2025InfuSystem Holdings, Inc. 3851 W. Hamlin Road Rochester Hills, MI 48309 248-291-1210 FOR IMMEDIATE RELEASE CONTACT Barry Steele Chief Financial Officer 248-260-2211 Ambulatory Infusion Pumps used in Pain Management Busin
InfuSystem Holdings, Inc. announced that the Centers for Medicare and Medicaid Services (CMS) will provide separate payment for its electronic infusion pumps under the NOPAIN Act starting January 1, 2026. This decision recognizes the CADD-SolisTM and SapphireTM pumps as effective non-opioid options for pain management. The initiative is intended to promote safer pain management alternatives and reduce reliance on opioids. InfuSystem's CEO expressed optimism about potential growth in their Pain Management business, although concerns remain regarding reimbursement understanding and customer adoption.
Read more →-INFU
Nov 10, 2025InfuSystem Holdings, Inc. 3851 W. Hamlin Road Rochester Hills, MI 48309 248-291-1210 FOR IMMEDIATE RELEASE CONTACT Joe Dorame, Joe Diaz Robert Blum Lytham Partners, LLC 602-889-9700 InfuSystem to Participate at 16th Annu
InfuSystem Holdings, Inc. has announced its participation in the upcoming 16th Annual Craig-Hallum Alpha Select Conference scheduled for November 18, 2025. Key executives, including President Carrie Lachance and CFO Barry Steele, will hold one-on-one meetings with investors. The company provides outpatient care services and operates under a dual platform model, addressing multiple segments of healthcare. However, they face potential risks regarding future growth and economic uncertainties.
Read more →-INFU
Nov 4, 2025▼ -9%on this news
InfuSystem Holdings, Inc. 3851 W. Hamlin Road Rochester Hills, MI 48309 248-291-1210 CONTACT Joe Dorame, Joe Diaz Robert Blum Lytham Partners, LLC 602-889-9700 InfuSystem Reports Third Quarter 2025 Financial Results Reco
InfuSystem Holdings, Inc. reported its third quarter 2025 financial results, achieving record net revenues of $36.5 million, a 3% increase from the previous year. The company also noted a 25% rise in net income to $2.3 million. While the Patient Services segment showed significant growth, the Device Solutions segment faced a decline. Management emphasized ongoing improvements and profitable growth strategies, although recent contract restructuring may impact future revenues in biomedical services.
Read more →-INFU
Oct 28, 2025InfuSystem Holdings, Inc. 3851 W. Hamlin Road Rochester Hills, MI 48309 248-291-1210 FOR IMMEDIATE RELEASE CONTACT Joe Dorame, Joe Diaz Robert Blum Lytham Partners, LLC 602-889-9700 InfuSystem to Report Third Quarter 202
InfuSystem Holdings, Inc. announced that it will report its third quarter financial results for 2025 on November 4, 2025, prior to market opening. An investor conference call will be held at 9 a.m. Eastern Time the same day, allowing stakeholders to discuss the financial outcomes. The call can be accessed via phone or live webcast. InfuSystem offers services under a two-platform model, focusing on outpatient care across various medical fields.
Read more →-INFU
Sep 25, 2025InfuSystem Holdings, Inc. 3851 W. Hamlin Road Rochester Hills, MI 48309 248-291-1210 FOR IMMEDIATE RELEASE CONTACT Joe Dorame, Joe Diaz Robert Blum Lytham Partners, LLC 602-889-9700 InfuSystem to Present at 4 th Annual R
InfuSystem Holdings, Inc. has announced its participation in the 4th Annual ROTH Healthcare Opportunities Conference scheduled for October 9, 2025. The company's CEO and CFO will represent InfuSystem at the event, highlighting its role as a significant national healthcare service provider. This participation reflects the company's commitment to providing outpatient care and engaging with investors. The conference will occur at the Metropolitan Club in New York City, with opportunities for virtual meetings for interested investors.
Read more →-INFU
Aug 5, 2025InfuSystem Holdings, Inc. 3851 W. Hamlin Road Rochester Hills, MI 48309 248-291-1210 CONTACT Joe Dorame, Joe Diaz Robert Blum Lytham Partners, LLC 602-889-9700 InfuSystem Reports Second Quarter 2025 Financial Results Rec
InfuSystem Holdings, Inc. reported robust financial results for the second quarter of 2025, with net revenues reaching $36.0 million, a 7% increase year-over-year. The company achieved a significant net income of $2.6 million, marking a 262% rise, and an adjusted EBITDA of $8.0 million, a 32% increase. However, the revenue growth outlook for the year was revised downward, reflecting anticipated challenges in specific segments. Despite this adjustment, the company reported strong cash flow and profitability improvements.
Read more →About InfuSystem Holdings, Inc.
Headquarters3851 WEST HAMLIN ROAD, ROCHESTER HILLS, MI, 48309
BIOPHARMAWATCH ELITE PLUS
Trade the next INFU catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime